1. Home
  2. NXTT vs BCDA Comparison

NXTT vs BCDA Comparison

Compare NXTT & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXTT
    SELLHOLDBUYas of 3 days ago
  • BCDA
    SELLHOLDBUYas of 3 days ago
  • Stock Information
  • Founded
  • NXTT 2019
  • BCDA N/A
  • Country
  • NXTT China
  • BCDA United States
  • Employees
  • NXTT N/A
  • BCDA N/A
  • Industry
  • NXTT
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • NXTT
  • BCDA Health Care
  • Exchange
  • NXTT NYSE
  • BCDA Nasdaq
  • Market Cap
  • NXTT 13.3M
  • BCDA 7.9M
  • IPO Year
  • NXTT N/A
  • BCDA N/A
  • Fundamental
  • Price
  • NXTT $1.90
  • BCDA $1.97
  • Analyst Decision
  • NXTT
  • BCDA Strong Buy
  • Analyst Count
  • NXTT 0
  • BCDA 1
  • Target Price
  • NXTT N/A
  • BCDA $25.00
  • AVG Volume (30 Days)
  • NXTT 108.9K
  • BCDA 35.7K
  • Earning Date
  • NXTT 11-15-2024
  • BCDA 11-13-2024
  • Dividend Yield
  • NXTT N/A
  • BCDA N/A
  • EPS Growth
  • NXTT N/A
  • BCDA N/A
  • EPS
  • NXTT 3.59
  • BCDA N/A
  • Revenue
  • NXTT $1,133,308.00
  • BCDA $71,000.00
  • Revenue This Year
  • NXTT N/A
  • BCDA N/A
  • Revenue Next Year
  • NXTT N/A
  • BCDA N/A
  • P/E Ratio
  • NXTT $0.54
  • BCDA N/A
  • Revenue Growth
  • NXTT N/A
  • BCDA N/A
  • 52 Week Low
  • NXTT $0.94
  • BCDA $1.63
  • 52 Week High
  • NXTT $6.66
  • BCDA $10.80
  • Technical
  • Relative Strength Index (RSI)
  • NXTT 46.05
  • BCDA 41.08
  • Support Level
  • NXTT $1.95
  • BCDA $1.63
  • Resistance Level
  • NXTT $2.52
  • BCDA $2.14
  • Average True Range (ATR)
  • NXTT 0.32
  • BCDA 0.19
  • MACD
  • NXTT -0.08
  • BCDA -0.02
  • Stochastic Oscillator
  • NXTT 6.98
  • BCDA 41.98

Stock Price Comparison Chart: NXTT vs BCDA

NXTT
BCDA
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober01234567891011121314NXTT VS BCDA

About NXTT NEXT TECHNOLOGY HOLDING INC

Next Technology Holding Inc pursues two corporate strategies. One business strategy is to continue providing software development services, and the other strategy is to acquire and hold Bitcoin. It provides AI-enabled software development services to its customers, which include developing, designing, and implementing various SAAS software solutions for businesses of all types, including industrial and other businesses. Its bitcoin acquisition strategy generally involves acquiring bitcoin with its liquid assets that exceed working capital requirements, and from time to time, subject to market conditions, issuing debt or equity securities or engaging in other capital raising transactions to use the proceeds to purchase bitcoin.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use